Trial Profile

Phase I/II First-in-Human Study of TT-10 (PORT-6), an Adenosine 2A Receptor Antagonist, and PORT-7, an Adenosine 2B Receptor Antagonist, as Single Agents and in Combination in Participants With Advanced Selected Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 21 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; PORT-6 (Primary) ; PORT-7 (Primary) ; Immune checkpoint protein inhibitors
Indications Non-small cell lung cancer; Prostate cancer; Renal cell carcinoma; Solid tumours
Focus Adverse reactions; First in man
Acronyms ADPORT-201; ADPORT-601; IMPORT
Sponsors Portage Biotech

15 Sep 2026 Planned number of patients changed from 90 to 35.
15 Sep 2026 Planned End Date changed from 31 Dec 2027 to 1 Mar 2029.
15 Sep 2026 Planned primary completion date changed from 1 Jun 2026 to 1 Dec 2028.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com